-
Something wrong with this record ?
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
C. Palmi, S. Bresolin, S. Junk, G. Fazio, D. Silvestri, M. Zaliova, A. Oikonomou, K. Scharov, M. Stanulla, A. Moericke, M. Zimmermann, M. Schrappe, B. Buldini, S. Bhatia, A. Borkhardt, C. Saitta, M. Galbiati, M. Bardini, L. Lo Nigro, V. Conter,...
Status not-indexed Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2017
PubMed Central
from 2017
Europe PubMed Central
from 2017
Wiley-Blackwell Open Access Titles
from 1997
- Publication type
- Journal Article MeSH
Children with Down syndrome have an augmented risk for B-cell acute lymphoblastic leukemia (DS-ALL), which is associated with lower survival than in non-DS-ALL. It is known that cytogenetic abnormalities common in childhood ALL are less frequent in DS-ALL, while other genetic aberrancies (ie, CRLF2 overexpression and IKZF1 deletions) are increased. A possible cause for the lower survival of DS-ALL that we herewith evaluated for the first time was the incidence and prognostic value of the Philadelphia-like (Ph-like) profile and the IKZF1plus pattern. These features have been associated with poor outcome in non-DS ALL and therefore introduced in current therapeutic protocols. Forty-six out of 70 DS-ALL patients treated in Italy from 2000 to 2014 displayed Ph-like signature, mostly characterized by CRLF2 (n = 33) and IKZF1 (n = 16) alterations; only 2 cases were positive for ABL-class or PAX5-fusion genes. Moreover, in an Italian and German joint cohort of 134 DS-ALL patients, we observed 18% patients positive for IKZF1plus feature. Ph-like signature and IKZF1 deletion were associated with poor outcome (cumulative incidence of relapse: 27.7 ± 6.8% versus 13 ± 7%; P = 0.04 and 35.2 ± 8.6% versus 17 ± 3.9%; P = 0.007, respectively), which further worsens when IKZF1 deletion was co-occurring with P2RY8::CRLF2, qualifying for the IKZF1plus definition (13/15 patients had an event of relapse or treatment-related death). Notably, ex vivo drug screening revealed sensitivity of IKZF1plus blasts for drugs active against Ph-like ALL such as Birinapant and histone deacetylase inhibitors. We provided data in a large setting of a rare condition (DS-ALL) supporting that these patients, not associated with other high-risk features, need tailored therapeutic strategies.
Biostatistics and Clinical Epidemiology Fondazione IRCCS San Gerardo dei Tintori Monza Italy
Center of Pediatric Hematology and Oncology Azienda Policlinico San Marco Catania Italy
Istituto di Ricerca Pediatrica Città della Speranza Padua Italy
Medical Genetics School of Medicine and Surgery University of Milan Bicocca Monza Italy
Pediatric Hematology and Oncology Hannover Medical School Hannover Germany
Pediatrics Fondazione IRCCS San Gerardo dei Tintori Monza Italy
School of Medicine and Surgery University of Milan Bicocca Italy
Statistics University of Milan Bicocca Monza Italy
Tettamanti Center Fondazione IRCCS San Gerardo dei Tintori Monza Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009634
- 003
- CZ-PrNML
- 005
- 20230721095522.0
- 007
- ta
- 008
- 230707s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HS9.0000000000000892 $2 doi
- 035 __
- $a (PubMed)37304931
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Palmi, Chiara $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 245 10
- $a Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia / $c C. Palmi, S. Bresolin, S. Junk, G. Fazio, D. Silvestri, M. Zaliova, A. Oikonomou, K. Scharov, M. Stanulla, A. Moericke, M. Zimmermann, M. Schrappe, B. Buldini, S. Bhatia, A. Borkhardt, C. Saitta, M. Galbiati, M. Bardini, L. Lo Nigro, V. Conter, MG. Valsecchi, A. Biondi, G. Te Kronnie, G. Cario, G. Cazzaniga
- 520 9_
- $a Children with Down syndrome have an augmented risk for B-cell acute lymphoblastic leukemia (DS-ALL), which is associated with lower survival than in non-DS-ALL. It is known that cytogenetic abnormalities common in childhood ALL are less frequent in DS-ALL, while other genetic aberrancies (ie, CRLF2 overexpression and IKZF1 deletions) are increased. A possible cause for the lower survival of DS-ALL that we herewith evaluated for the first time was the incidence and prognostic value of the Philadelphia-like (Ph-like) profile and the IKZF1plus pattern. These features have been associated with poor outcome in non-DS ALL and therefore introduced in current therapeutic protocols. Forty-six out of 70 DS-ALL patients treated in Italy from 2000 to 2014 displayed Ph-like signature, mostly characterized by CRLF2 (n = 33) and IKZF1 (n = 16) alterations; only 2 cases were positive for ABL-class or PAX5-fusion genes. Moreover, in an Italian and German joint cohort of 134 DS-ALL patients, we observed 18% patients positive for IKZF1plus feature. Ph-like signature and IKZF1 deletion were associated with poor outcome (cumulative incidence of relapse: 27.7 ± 6.8% versus 13 ± 7%; P = 0.04 and 35.2 ± 8.6% versus 17 ± 3.9%; P = 0.007, respectively), which further worsens when IKZF1 deletion was co-occurring with P2RY8::CRLF2, qualifying for the IKZF1plus definition (13/15 patients had an event of relapse or treatment-related death). Notably, ex vivo drug screening revealed sensitivity of IKZF1plus blasts for drugs active against Ph-like ALL such as Birinapant and histone deacetylase inhibitors. We provided data in a large setting of a rare condition (DS-ALL) supporting that these patients, not associated with other high-risk features, need tailored therapeutic strategies.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bresolin, Silvia $u Women's and Children's Health Department, Hematology-Oncology Clinic and Laboratory, University-Hospital of Padua, Italy $u Istituto di Ricerca Pediatrica-Città della Speranza, Padua, Italy
- 700 1_
- $a Junk, Stefanie $u Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Fazio, Grazia $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Silvestri, Daniela $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Zaliova, Marketa $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Oikonomou, Athanasios $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Scharov, Katerina $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, Düsseldorf, Germany
- 700 1_
- $a Stanulla, Martin $u Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Moericke, Anja $u Pediatrics, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Zimmermann, Martin $u Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Schrappe, Martin $u Pediatrics, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Buldini, Barbara $u Women's and Children's Health Department, Hematology-Oncology Clinic and Laboratory, University-Hospital of Padua, Italy $u Istituto di Ricerca Pediatrica-Città della Speranza, Padua, Italy
- 700 1_
- $a Bhatia, Sanil $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, Düsseldorf, Germany
- 700 1_
- $a Borkhardt, Arndt $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, Düsseldorf, Germany
- 700 1_
- $a Saitta, Claudia $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Galbiati, Marta $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Bardini, Michela $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Lo Nigro, Luca $u Center of Pediatric Hematology and Oncology, Azienda Policlinico-San Marco, Catania, Italy
- 700 1_
- $a Conter, Valentino $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Valsecchi, Maria Grazia $u Statistics, University of Milan Bicocca, Monza, Italy $u Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 700 1_
- $a Biondi, Andrea $u Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy $u School of Medicine and Surgery, University of Milan Bicocca, Italy
- 700 1_
- $a Te Kronnie, Geertruy $u Women's and Children's Health Department, Hematology-Oncology Clinic and Laboratory, University-Hospital of Padua, Italy
- 700 1_
- $a Cario, Gunnar $u Pediatrics, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Cazzaniga, Giovanni $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy $u Medical Genetics, School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
- 773 0_
- $w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 7, č. 6 (2023), s. e892
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37304931 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095515 $b ABA008
- 999 __
- $a ok $b bmc $g 1958441 $s 1195898
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 7 $c 6 $d e892 $e 20230526 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
- LZP __
- $a Pubmed-20230707
